Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089739 · ClinicalTrials.gov registry record
Immune Indicators of Uveitis
A clinical trial of Uveitis and Immunosuppression, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT00089739 is a study of Uveitis and Immunosuppression that has completed, run by National Eye Institute (NEI). The registered enrollment target is 100 participants, below the 612-participant average among 19 other Uveitis trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00089739, a study of Uveitis and Immunosuppression, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will try to identify markers of immune activity in uveitis patients that correlate with the state of disease activity. Uveitis is a group of inflammatory eye diseases that can cause vision loss. The study will examine whether certain substances in the blood can predict a reactivation of disease before it occurs, and how therapy may influence the activity of these substances. Previous studies have found some possible markers called GITR (glucocorticoid induced TNF related family receptor), SOCS (suppressors of cytokine secretion), and interleukin-15. Markers such as these may help guide physicians in safely tapering medicines in uveitis patients. Patients 18 years of age and older with sight-threatening uveitis may be eligible for this study. Participants are slowly tapered off their medicines when their disease is stable and there is no evidence of significant inflammation. If the disease remains inactive during tapering, all drug therapy is eventually stopped. Patients have eye examinations about every 1 to 3 months when the disease is quiet and every 2 to 4 weeks during flare-ups. Blood samples are drawn 2 to 3 times a year. In addition, patients may have the following procedures if needed: * Eye photography: Eye drops are given to enlarge the pupils for a thorough eye examination, and a special camera is used to take photographs. * Fluorescein angiography: This test checks for abnormalities of eye blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken with a special camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible abnormalities.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2004-08-09 |
| Est. Completion | 2008-10-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089739
The ClinicalTrials.gov registry entry for NCT00089739 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 612-participant average among 19 other Uveitis trials with a reported enrollment target (84% lower). The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Uveitis appearing as the primary indexed condition, and to 0 interventions.
NCT00089739 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00089739 about?
NCT00089739 is a clinical study titled "Immune Indicators of Uveitis". This study will try to identify markers of immune activity in uveitis patients that correlate with the state of disease activity. Uveitis is a group of inflammatory eye diseases that can cause vision loss. The study will examine whether certain substances in the blood can predict a reactivation of d...
What is the current status of trial NCT00089739?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2004-08-09. Estimated completion is 2008-10-28.
What conditions does trial NCT00089739 study?
This clinical trial studies the following conditions: Uveitis, Immunosuppression, GITR, GITR Ligand, Suppressor of Cytokine Secretion.
Who is sponsoring clinical trial NCT00089739?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00089739 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
RECRUITING
-
Genetics of Uveitis
RECRUITING
-
Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography
RECRUITING
-
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
RECRUITING · NA
-
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
RECRUITING · Phase 3
-
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.